Cost containment in healthcare is the effort to reduce spending, or at least slow how fast it grows, without sacrificing the quality of care patients receive or their ability to access it. With roughly $1 trillion of U.S. healthcare dollars going to administrative services alone each year (20% to 25% of total spending), the opportunities to cut waste are enormous. Cost containment operates on multiple fronts simultaneously: how providers get paid, how drugs are priced, how hospitals buy supplies, and how insurers decide which services to approve.
What Cost Containment Actually Means
The formal definition is straightforward: reducing the level or rate of increase in healthcare costs. That distinction matters. Sometimes the goal is to bring actual spending down. More often, it’s about keeping costs from climbing as steeply as they otherwise would. A strategy that holds annual spending growth to 3% instead of 7% counts as containment even if total spending still rises.
The challenge is doing this without creating harm. Cutting payments to hospitals or doctors can reduce costs on paper, but if it leads to shorter appointments, fewer staff, or longer wait times, patients pay a different price. The working assumption behind most cost containment policy is that the healthcare system contains enough inefficiency, duplication, and waste that spending can shrink through smarter operations rather than rationing care. Whether that assumption holds depends entirely on which strategies get used and how aggressively they’re applied.
National policy generally focuses on containing total expenditures rather than simply shifting costs from one payer to another. If an insurer negotiates a lower rate but the hospital raises prices for uninsured patients to compensate, nothing has actually been contained. The spending just moved.
How Payment Models Drive Spending
One of the most direct levers for cost containment is changing how providers get paid. Traditional fee-for-service medicine rewards volume: the more tests, procedures, and visits a provider bills, the more they earn. Newer payment models flip that incentive.
Bundled payments give providers a single fixed amount for an entire episode of care. A hip replacement, for example, might come with one payment that covers the surgery, hospital stay, rehabilitation, and follow-up visits. If the provider delivers that care efficiently and the patient recovers well, the provider keeps the savings. If complications arise from poor coordination, the provider absorbs the extra cost. This structure pushes hospitals and clinics to think about the full arc of a patient’s recovery rather than each billable moment within it.
In practice, providers participating in bundled payment programs often hire care navigators who guide patients through recovery, improve communication between surgeons, primary care doctors, and physical therapists, and share data across teams so everyone works from the same playbook. The result is fewer avoidable hospital readmissions and more patients recovering at home instead of in costly inpatient settings.
Managed Care and Prior Authorization
Managed care organizations use a toolkit of controls to influence which services patients receive and from whom. The most familiar of these is prior authorization, which requires a provider to get approval from the insurer before ordering certain medications, tests, or procedures. The stated purpose is ensuring that patients receive clinically appropriate, affordable treatments rather than defaulting to the most expensive option when a cheaper alternative works just as well.
Prior authorization criteria are typically built from clinical trial data, peer-reviewed research, and consensus guidelines. For medication classes where multiple drugs exist with varying effectiveness and cost, prior authorization steers prescribing toward preferred options on the insurer’s formulary. Critics argue the process creates delays and administrative headaches that can interfere with care. Supporters counter that without it, unnecessary spending spirals quickly. As more providers enter risk-sharing arrangements with insurers, prior authorization is evolving toward shared decision-making rather than top-down gatekeeping.
Controlling Prescription Drug Costs
Prescription drugs are one of the fastest-growing categories of healthcare spending, and the strategies used to contain them are layered.
Formularies are the foundation. A formulary is simply a list of drugs that an insurance plan will cover. Plans use tiered formularies that sort medications into categories based on cost and clinical evidence. A generic cholesterol drug might sit on the lowest-cost tier with a small copay, while a brand-name version of the same class of drug lands on a higher tier with a steeper out-of-pocket cost. This structure nudges both doctors and patients toward less expensive options without removing access to alternatives entirely.
Behind the scenes, pharmacy benefit managers negotiate rebates with drug manufacturers. Rebates are essentially delayed discounts: a manufacturer agrees to return a percentage of revenue on a drug in exchange for favorable placement on the formulary. These rebates can substantially reduce a plan’s net drug costs. The manufacturer pays based on how much of their product gets dispensed, and the pharmacy benefit manager typically takes a fee or percentage for handling the negotiation. Whether those savings consistently reach patients in the form of lower prices at the pharmacy counter is an ongoing debate.
Hospital Supply Chains and Group Purchasing
Over 95% of U.S. hospitals use group purchasing organizations to buy medications, devices, and supplies. The concept is simple: hospitals band together to negotiate bulk pricing they could never get individually. A single hospital buying surgical gloves has little leverage. Thousands of hospitals buying through the same organization can demand steep discounts.
Group purchasing organizations also reduce administrative burden. Instead of each hospital independently evaluating vendors, negotiating contracts, and managing procurement, the organization handles it centrally. The savings come from both lower unit prices and fewer hours spent on purchasing logistics. These organizations have also accelerated the adoption of lower-cost alternatives like biosimilar drugs (near-identical versions of expensive biologic medications), which translates to savings for both payers and patients.
Cutting Administrative Waste
Administrative spending consumes roughly 20% to 25% of all U.S. healthcare dollars, amounting to an estimated $1 trillion annually. For hospitals specifically, administrative expenses account for about 17% of total costs. This includes billing, coding, claims processing, compliance, credentialing, and the enormous paperwork infrastructure that sits between a patient receiving care and someone paying for it.
Artificial intelligence is beginning to chip away at this. AI-powered systems can flag billing anomalies and potential fraud far faster than manual audits, potentially recovering billions in wasted resources. Healthcare fraud alone costs the system enormous sums each year, and automated detection catches patterns that human reviewers miss. Beyond fraud, AI tools are streamlining claims processing, reducing coding errors, and shortening the cycle between service delivery and payment.
The federal government is also pushing efficiency adjustments. In the 2026 Medicare Physician Fee Schedule, CMS finalized a 2.5% efficiency adjustment for select services, reflecting the expectation that certain procedures naturally become less resource-intensive over time. In one striking example, CMS restructured how it pays for skin substitute products (used in wound care), a change projected to reduce Medicare spending on those products by nearly 90%, saving an estimated $19.6 billion in 2026 alone, while still preserving patient access.
Preventive Care as a Long-Term Strategy
Preventing disease is almost always cheaper than treating it, but the savings take time to materialize. A Canadian study of 22 primary care practices serving over 90,000 patients found that investing in outreach facilitators (nurses who helped practices improve their screening protocols) cost about $238,000 per year. By reducing inappropriate tests patients didn’t need and increasing appropriate screenings that caught problems early, the program saved $604,000 annually. That’s a 40% return on investment, with net savings of roughly $3,700 per physician per year.
The savings came from two directions. Eliminating unnecessary screening tests saved money directly. Catching conditions through appropriate testing avoided the far higher costs of treating diseases that had progressed because they went undetected. This dual benefit, spending less on waste while spending smarter on prevention, is the clearest illustration of what effective cost containment looks like in practice.
The Tension Between Savings and Quality
Every cost containment strategy carries a risk of going too far. Prior authorization can delay necessary care. Formulary restrictions can push patients toward medications that are cheaper but less effective for their specific situation. Payment caps can pressure hospitals to discharge patients earlier than ideal. The core assumption behind cost containment, that efficiency gains can absorb the cuts, holds true only when the strategies target genuine waste rather than essential services.
The most sustainable approaches tend to be those that align financial incentives with patient outcomes. Bundled payments reward providers for keeping patients healthy after a procedure. Preventive care programs pay for themselves by avoiding expensive crises down the road. Group purchasing lowers costs without touching clinical decisions at all. The strategies that generate the most friction are those that insert a financial decision between a provider and a patient, like prior authorization or restrictive formularies, where the line between reducing waste and restricting access can blur.